Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:367-79.

The changing face of hypophosphatemic disorders in the FGF-23 era.

Author information

1
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Abstract

In the past decade, research in genetic disorders of hypophosphatemia has significantly expanded our understanding of phosphate metabolism. X-linked hypophosphatemia (XLH) is the most common inherited form of rickets due to renal phosphate wasting. Recent understanding of the mechanisms of disease and role of fibroblast growth factor 23 (FGF-23) in XLH and other hypophosphatemic disorders have opened new potential therapeutic avenues. We will discuss the current standard of treatment for XLH as well as promising future directions under study.

PMID:
23858620
PMCID:
PMC4170520
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center